Candida albicans is an opportunistic yeast that causes severe disease in immunocompromised individuals. Oropharyngeal candidiasis, for example, is one of the most common opportunistic infections of individuals undergoing immunosuppressive therapy for cancer (6) or organ transplantation and in patients with AIDS (10) . The synthetic triazole fluconazole has several advantages over earlier imidazoles, such as ketoconazole, in the treatment of patients with severe candidiasis. It has a higher solubility in water, a longer plasma half-life (31 h), and a relatively low toxicity (3) . Between 1988 and 1993, fluconazole was used to treat over 15 million patients, including at least 250,000 AIDS patients (18) , and fluconazole treatment of patients with oropharyngeal candidosis has been adopted by many clinics (48) . However, recently there has been an increased incidence of treatment failures in candidiasis patients receiving prolonged fluconazole therapy (8, 13, 27, 42) , and these treatment failures have been shown to be due to reduced susceptibility of C. albicans to fluconazole (40) . Resistance of Candida spp. to fluconazole has been reported more frequently than resistance to ketoconazole, and there have been few reports of resistance to the less frequently prescribed itraconazole (34) . The ketoconazole-resistant C. albicans AD, KB, and Darlington strains have been well studied (19, 20, 23, 43, 49) , and ketoconazole has been shown to enter C. albicans by diffusion and by an energy-dependent uptake system (7) . In contrast, little is known about fluconazole uptake in C. albicans.
Fluconazole resistance in C. albicans may occur in two ways: reduced fluconazole accumulation or an altered drug target (14␣-sterol demethylase, encoded by ERG16). There is no evidence that fluconazole is modified and inactivated by C. albicans. A few fluconazole-resistant C. albicans strains show overexpression of ERG16 mRNA, but this is probably not the major cause of resistance in these isolates (44) . Evidence suggests that a common resistance mechanism is reduced fluconazole accumulation (44, 50) , either as a result of reduced cellular uptake or increased efflux. Two genes encoding proteins thought to be associated with drug efflux have been identified in C. albicans. The BEN r gene (12) encodes a protein from the major facilitator superfamily of transporters (30) and confers resistance to benomyl and methotrexate when expressed in Saccharomyces cerevisiae (12) . The C. albicans CDR1 gene (38) encodes an ATP-binding cassette-type transporter (16) which complements the ⌬pdr5 mutation in S. cerevisiae associated with susceptibility to cycloheximide (38) . A number of fluconazole-resistant C. albicans isolates from AIDS patients show increased amounts of Cdr1 mRNA, implicating a role for this protein in azole resistance (44) . To clarify further the role of putative drug efflux proteins in C. albicans azole resistance, we have isolated an isogenic fluconazole-resistant mutant of C. albicans SGY-243. This allows the direct comparison of the expression of putative drug efflux-associated genes in the isogenic mutant with those in parental strains, as well as with those in several well-characterized azole-resistant isolates. Our results suggest that fluconazole resistance could be associated with elevated Ben r expression while azole resistance could be associated with elevated Cdr1 expression.
MATERIALS AND METHODS
Yeast strains. The C. albicans strains used in this study are listed in Table 1 . Isolation of a fluconazole-resistant mutant of C. albicans SGY-243. A fluconazole-resistant mutant of C. albicans SGY-243 (ade2/ade2 ⌬ura3::ADE2/ ⌬ura3::ADE2) was isolated by serial passage through media containing fluconazole. C. albicans SGY-243 cells were incubated in RPMI 1640 medium (Life Technologies, Gaithersburg, Md.) containing uridine (50 g/ml) (RPMI ϩ Uri) at 30ЊC for 16 h with shaking and were diluted into fresh RPMI ϩ Uri at a concentration of 4.4 ϫ 10 6 cells per ml. The culture was incubated at 30ЊC for 4.5 h, and then fluconazole was added at a final concentration of 1 g/ml (twice the MIC [see Table 2 ]). After 4.5 h of further incubation, growth of the culture reached a plateau at a cell density of 3.5 ϫ 10 7 cells per ml, whereas a control culture (without fluconazole) had a cell density of 6.6 ϫ 10 7 cells per ml. After additional incubation (50 h), cells at concentration of 3.3 ϫ 10 6 cells per ml were subcultured from the fluconazole-containing culture into fresh RPMI ϩ Uri with fluconazole and incubated at 30ЊC with shaking. After [20 g/liter] ) containing fluconazole (0, 0.5, 1.0, or 2 g/ml). One colony was picked from the plate containing 2 g of fluconazole per ml and tested for growth on minimal agar containing higher fluconazole concentrations (4, 8, 16 , or 32 g/ml). After 24 h of incubation at 30ЊC, colonies had grown on all plates, although colonies were smaller on plates containing 32 g of fluconazole per ml. A single colony was picked from the plate containing 32 g of fluconazole per ml and was designated isolate FR2.
Determinations of MICs of antifungal agents. The MICs of antifungal agents for C. albicans strains were determined by a microdilution test based on the macrodilution reference method of the National Committee for Clinical Laboratory Standards (11, 14, 36) .
(i) Antifungal agents. Stock solutions (10 mg/ml) of fluconazole (Pfizer Ltd., Sandwich, Kent, United Kingdom), ketoconazole (Janssen Research Foundation, Beerse, Belgium), itraconazole (Janssen Research Foundation), amphotericin B (E. R. Squibb & Sons, Princeton, N.J.), benomyl (Nippon Roche, Kamakura, Japan), cycloheximide (Sigma), and methotrexate (Nippon Roche) were prepared in either dimethyl sulfoxide (ketoconazole, itraconazole, amphotericin B, benomyl, and methotrexate), sterile water (fluconazole), or RPMI medium (cycloheximide) immediately prior to use.
(ii) Inoculum. The yeast cell inoculum was prepared from a culture grown in RPMI buffered with MOPS (morpholinepropanesulfonic acid) (165 mM, pH 6.8) at 30ЊC for 16 h. The RPMI medium was supplemented with uridine (50 g/ml) for the growth of C. albicans SGY-243 and FR2. For determinations of the MIC of methotrexate, the folate pool of the inoculum was reduced (15) by growing the yeast in glucose-salts-biotin medium (GSB [22] ) and the MIC determinations were carried out in GSB containing sulfanilamide (200 g/ml, from 20-mg/ml acetone stock). The relationship between the optical densities of cultures and the numbers of CFU per milliliter was determined for each strain by plating cell dilutions on agar plates and counting the colonies formed after incubation of plates at 30ЊC for 48 h. The inoculum was added to the plates for the MIC determinations to give a final concentration of 3 ϫ 10 4 CFU/ml. (iii) MIC test. MIC assays were performed in a final volume of 100 l in sterile plastic 96-well flat-bottom microtiter plates with covers (Greiner GmbH, Frickenhausen, Austria), with serial twofold antifungal agent dilutions in RPMI medium or in GSB for the determination of MICs of methotrexate. The final antifungal agent concentration ranges were 4 to 0.0078 g/ml for amphotericin B, ketoconazole, and itraconazole, 128 to 0.25 g/ml for fluconazole, 200 to 0.39 g/ml for benomyl and methotrexate, and 1,000 to 1.95 g/ml for cycloheximide. Uninoculated and drug-free controls were included. Inoculated microtiter plates were incubated at 30ЊC for 48 h on a rotary shaker (150 rpm). The plates were then agitated more vigorously to ensure homogeneous yeast cell suspensions, and the optical densities (at 492 nm) of suspensions were measured with an EAR 340 microtiter plate reader (SLT-Lab Instruments, Salzburg, Austria).
(iv) End point criterion. The optical density reading for each suspension was plotted against the antifungal agent concentration, and the MIC test end point was defined as the lowest antifungal concentration which gave Ͼ80% inhibition of growth compared with drug-free controls (36) .
Biotyping of C. albicans strains by DNA fingerprinting. The genetic similarities of C. albicans strains were determined by DNA fingerprinting using a moderately repetitive C. albicans probe, as described by Schmid et al. (45) . Genomic DNA was isolated from mid-exponential-phase yeast cells, digested with EcoRI, and electrophoresed on a 0.8% (wt/vol) agarose gel. The DNA fragments were vacuum blotted onto nylon membranes and hybridized with [20 g/liter] ) at 30ЊC to early log phase (optical density at 540 nm, 1.5), harvested by centrifugation (3,000 ϫ g, 5 min), and washed in 0.1 M phosphate buffer (pH 7.4) supplemented with 20 mM glucose. The cells (1 ml, 5 ϫ 10 8 CFU) were incubated at 30ЊC for 20 min, and then [ 3 H]fluconazole was added at a final concentration of 1 M. Samples (100 l) were removed at various times and placed into 1 ml of ice-cold wash buffer (WB; 0.1 M phosphate buffer [pH 7.4] containing 1 mM unlabelled fluconazole), filtered on glass fiber filters (GF/C; Whatman, Kent, United Kingdom) prewetted with WB, and washed four times with 1 ml of WB. The filters were transferred to scintillation vials, scintillation cocktail (Optiphase HiSafe; Wallac Oy, Turku, Finland) was added, and the radioactivity associated with the filters was measured with a liquid scintillation counter.
Amino acid uptake by yeast cells. The rate of amino acid uptake by yeast cells was determined with a uniformly 14 C-labelled amino acid mixture (specific activity, 2.11 GBq/mmol; Amersham). Cells were grown and prepared as described for the fluconazole uptake experiments. The cells (1 ml; 5 ϫ 10 8 CFU in 0.1 M phosphate buffer [pH 7.4] supplemented with 20 mM glucose) were incubated at 30ЊC for 20 min, and then uniformly 14 C-labelled amino acid mixture was added to a final concentration of 4.4 M. Samples (100 l) were removed at various times and placed into 1 ml of ice-cold 100 mM LiCl, filtered on GF/C filters (prewetted with 100 mM LiCl), and washed four times with ice-cold 100 mM LiCl (1 ml). The radioactivity associated with the filters was counted as described above.
Analysis of mRNA in C. albicans strains. C. albicans cells were grown in YPD medium at 30ЊC with shaking until the culture reached mid-exponential phase. Cells (1.76 ϫ 10 9 ) were harvested by centrifugation (4,000 ϫ g, 5 min at 4ЊC) and washed three times with diethyl pyrocarbonate-treated water (5), and the RNA was extracted by the method of Schmitt et al. (46) . Serial dilutions of RNA were vacuum blotted onto nylon membranes and then hybridized under high-stringency conditions with [
32 P]dCTP-labelled PCR-generated CDR1 (38) , BEN r (12), ERG16 (L1A1 [28] ), or ACT1 (29) probe. The probes were PCR amplified from C. albicans ATCC 10261 genomic DNA by using the following oligonucleotides: CDR1, 5ЈTTATGTCCAACAACAAGATGTTC3Ј and 5ЈCTGTACATG AAAATCCAAAATCC3Ј; BEN r , 5ЈTGAGATTCTTGGGTGGATTCTTCG3Ј and 5ЈGGTGGCCAAATTGTCAAACAAAGG3Ј; ERG16, 5ЈATGGGTGGTC AACATACTTC3Ј and 5ЈCTTCATCAGAAGAGTTAAATC3Ј; and ACT1, 5ЈA CTTCTTCTCAATCTTCTGCC3Ј and 5ЈAATGGATGGACCAGATTCGTCG 3Ј. The probes were partially sequenced to confirm their identities. The membranes were exposed to X-ray film, and the signals on the autoradiograms were quantified with a laser densitometer. The signals generated with the CDR1, BEN r , and ERG16 probes were expressed relative to the ACT1 signals to correct for unequal RNA loading. The labelled probes were hybridized on Northern (RNA) blots as described previously (9) .
RESULTS
Characterization of a fluconazole-resistant mutant of C. albicans SGY-243. C. albicans FR2 was isolated as a fluconazoleresistant mutant of strain SGY-243 following serial passage through media containing fluconazole (see Materials and Methods). C. albicans FR2, like the parental strain SGY-243, was Ura Ϫ , and the patterns of the EcoRI genomic DNA bands that hybridized to the Ca3 moderately repetitive C. albicans probe (45) for these strains were identical, showing that they were isogenic. The MIC of fluconazole for FR2 grown in RPMI ϩ Uri was 32 g/ml ( Table 2 ). The doubling time of FR2 cells in RPMI ϩ Uri (1.72 h) was slightly greater than that of strain SGY-243 (1.38 h). The fluconazole resistance phenotype in FR2 was stable; cells grown for 20 generations in the absence of fluconazole retained the same resistance to fluconazole.
Cross-resistance of various C. albicans strains to antifungal agents. The MICs of fluconazole, itraconazole, ketoconazole, and amphotericin B for FR2 and other azole-resistant strains of C. albicans were determined ( Table 2 ). The strains were designated as susceptible or resistant to each antifungal agent according to the reported ranges of the MICs of the antifungal agents for susceptible C. albicans strains (14, 33, 39, 47) . Resistant organisms were defined as those for which the MICs of the following antifungal agents were as indicated: fluconazole, Ͼ10 g/ml; itraconazole, Ͼ2 g/ml; ketoconazole, Ͼ0.5 g/ml; and amphotericin B, Ͼ1 g/ml. C. albicans ATCC 10261 and SGY-243 were susceptible to all antifungal agents tested, and strain FR2 was resistant only to fluconazole ( (Fig. 1) . The rate of fluconazole accumulation by FR2 was 6.7-fold lower than that by SGY-243 and approached a maximum after 15 min. There was no fluconazole accumulation by heat-killed SGY-243 cells (Fig. 1) or by cells that were incubated at 4ЊC (data not shown). The initial rates of fluconazole accumulation for other C. albicans strains were measured (Table 2). All fluconazole-resistant C. albicans strains, except for Darlington, showed a reduced rate of drug accumulation compared with susceptible strains (Table 2) .
Preincubation (30ЊC, 20 min) of C. albicans SGY-243 cells with sodium azide (20 mM) did not affect fluconazole accumulation significantly (Fig. 2) . Under the same conditions, azide completely abolished amino acid uptake (data not shown). This suggested that fluconazole accumulation by C. albicans SGY-243 was not energy dependent. Replacement of glucose in the uptake assay buffer by the glycolysis inhibitor 2-deoxyglucose had no effect on the accumulation of fluconazole by C. albicans SGY-243 (data not shown). Azide also had no effect on the net rate of fluconazole uptake by the fluconazole-susceptible wild-type strain C. albicans ATCC 10261 or on the net rate of fluconazole uptake by the resistant strain Darlington (Table 3) . However, azide treatment increased the net rate of fluconazole uptake by cells of all the other fluconazole-resistant C. albicans strains in this study, i.e., FR2 (Fig. 2) , B59630, AD, and KB. To determine whether ketoconazole interfered with fluconazole accumulation in C. albicans, the uptake of fluconazole by C. albicans SGY-243 was measured in the presence of unlabelled ketoconazole. The net uptake of fluconazole was not affected significantly by the presence of 10 M ketoconazole (1.90 pmol/min per 10 9 cells) or 100 M ketoconazole (1.68 pmol/min per 10 9 cells) in the uptake assay. In a separate experiment, the relationship between the rate of fluconazole accumulation by C. albicans SGY-243 and the fluconazole concentration was not linear, as would be expected for simple diffusion, and uptake became saturated at fluconazole concentrations of Ͼ20 M (Fig. 3 ). CDR1 and BEN r mRNA levels in C. albicans cells. In view of the evidence that Cdr1 and/or Ben r could be associated with drug resistance in C. albicans (38, 44) , we compared the amounts of these mRNAs in fluconazole-resistant strains with those in fluconazole-susceptible strains. The amount of ACT1 mRNA (encoding actin) in total RNA was also measured to standardize RNA levels and was found to be similar in all strains. In addition, all RNA preparations contained similar amounts of PMA1 (31) mRNA, which encodes the plasma membrane proton ATPase (data not shown). The amounts of CDR1 mRNA relative to ACT1 mRNA in fluconazole-resistant strains were significantly higher (2-to 17-fold) than those in fluconazole-susceptible strains (Fig. 4) . There was little variation in the amount of ERG16 mRNA in each strain, and the amount of signal generated with this probe was low (Fig. 5) . FR2 was the only strain to show overexpression of BEN r mRNA. It is important to note that the relative intensities of signals generated by the different probes cannot be compared as probe length and specific activity varied. However, for each probe strain-specific variations in amounts of mRNA can be measured. Each probe hybridized with only one band on Northern blots of total RNA extracted from C. albicans SGY-243 or FR2 (Fig. 5 [ (12, 15) . Since C. albicans FR2 overexpressed BEN r mRNA, we measured the susceptibilities of cells to these drugs. C. albicans FR2 cells were no more resistant to benomyl or methotrexate than were SGY-243 cells. The MICs of benomyl or methotrexate for all strains were greater than 100 or 200 g/ml, respectively. The fluconazole-susceptible strains ATCC 10261 and SGY-243 were relatively susceptible to cycloheximide (MIC, 250 and 125 g/ml, respectively). C. albicans FR2 and all the other azoleresistant strains were resistant to cycloheximide (MIC, Ͼ1,000 g/ml).
DISCUSSION
Fluconazole-resistant Candida spp. are a significant problem for patients undergoing long-term fluconazole treatment (13, 27, 32, 41) . In some cases, replacement of susceptible strains by a resistant strain has been shown to occur during fluconazole therapy (2, 37) , and in other cases, a single strain has developed reduced susceptibility to fluconazole during treatment (2, 40) . There is also heterogeneity in the cross-resistance pattern of fluconazole-resistant clinical isolates to other antifungal agents (13, 25, 32, 42, 49) . Some fluconazole-resistant strains are cross-resistant to ketoconazole (13, 42, 49) , fewer are crossresistant to itraconazole (25, 49) , and very few are resistant to amphotericin B (32) . Therefore, either progressive alterations in a mechanism of resistance, such as drug permeability, gives cross-resistance to a wider variety of antifungal agents or there are several separate resistance mechanisms. The C. albicans strains used in this study showed a spectrum of susceptibilities to antifungal agents.
Fluconazole-susceptible Candida albicans cells accumulated fluconazole at rates similar to those reported by Hitchcock et al. (21) for Candida glabrata (1.65 pmol/min per 10 9 cells) and similar to the net uptake of triazole ICI 153066 by C. albicans (2.52 pmol/min per 10 9 cells). There was no accumulation of fluconazole when C. albicans cells were incubated on ice, and the metabolic inhibitors sodium azide and 2-deoxyglucose had a negligible effect on uptake by fluconazole-susceptible cells. Also, the rate of fluconazole accumulation became saturated at high fluconazole concentrations. These results suggest that fluconazole entered cells of susceptible strains by facilitated diffusion. Fluconazole has a structure significantly different from that of ketoconazole and displays correspondingly different pharmacokinetics. Fluconazole is a polar molecule and, compared with ketoconazole, is relatively soluble in water. The uptake of ketoconazole at concentrations higher than 0.19 M occurs by simple diffusion, whereas at lower concentrations its accumulation appears to be an active, energy-dependent process (7) . The fact that ketoconazole did not affect the accumulation of fluconazole by C. albicans cells is further evidence that these compounds might enter the cells by distinct mechanisms. Fluconazole-resistant C. albicans FR2 was obtained after prolonged incubation in the presence of fluconazole, which mimicked the clinical situation. Strain FR2 was shown to have a DNA fingerprint identical to that of the parental strain SGY-243, and this genetic similarity enabled the study of factors related specifically to fluconazole resistance. Fluconazole-resistant C. albicans FR2, B59630, AD, and KB had much lower rates of fluconazole accumulation than did the susceptible strains. C. albicans AD and KB were originally isolated from patients who suffered ketoconazole treatment failure (43) . These strains showed negligible accumulation of triazole ICI 153066 (43) , and an alteration in membrane sterol composition (19) was proposed to be responsible for their low-level triazole accumulation and hence their azole resistance. C. albicans Darlington was unusual in that it accumulated fluconazole at a higher rate than did the fluconazole-susceptible strains, and this accumulation was not affected by azide. The 14␣-sterol demethylase in this strain has been shown to be less sensitive to the triazole ICI 153066 (20) ; however, there was no correlation between the 50% inhibitory concentrations for triazole inhibition of the demethylase and the 50% inhibitory concentrations for growth inhibition. Strain Darlington is also unusual in being resistant to amphotericin B. Triazole resistance in Darlington may be the result of multiple mechanisms, including a defective ⌬ 5,6 sterol desaturase (enzyme involved in sterol biosynthesis) (18, 23) . C. albicans B59630 is a less well-characterized azole-resistant clinical isolate. It was highly resistant to fluconazole and showed the lowest rate of net accumulation. Thus, a consistent feature of these fluconazole-resistant strains was, with the exception of Darlington, a reduced ability to accumulate fluconazole.
While azide treatment had no effect on fluconazole accumulation by fluconazole-susceptible strains, in fluconazole-resistant C. albicans FR2, B59360, AD, and KB, the net fluconazole uptake was increased by azide treatment. This provides evidence that the resistance mechanism is energy dependent and may be accounted for by fluconazole efflux as recently proposed for drug-resistant C. glabrata (35) .
In support of the notion that Cdr1, an ATP-binding cassettetype transporter with sequence similarity to S. cerevisiae Pdr5 (1), might be involved in azole resistance (44) , all fluconazoleresistant C. albicans strains were found to contain increased amounts of CDR1 mRNA. Furthermore, with the exception of strain Darlington, there was a correlation between the amount of CDR1 mRNA and the azide-sensitive rate of fluconazole accumulation, taken to indicate the approximate rate of efflux. Strain FR2 was unusual in that as well as being resistant only to fluconazole, it was the only strain to show increased amounts of BEN r mRNA as well as CDR1 mRNA. The C. albicans CDR1 and BEN r genes are currently implicated in drug resistance. Both genes were cloned originally from C. albicans libraries by conferring resistance to cycloheximide, chloramphenicol, and miconazole (CDR1) (38) VOL. 40, 1996 FLUCONAZOLE EFFLUX BY C. ALBICANS 2839 on February 21, 2013 by PENN STATE UNIV http://aac.asm.org/ C. albicans did not lead to benomyl resistance (15) , suggesting alternate mechanisms for this resistance in C. albicans. This is supported by the present work, which showed that isogenic mutant strain FR2 contained much more BEN r mRNA than did strain SGY-243 but was not significantly more resistant to benomyl or methotrexate. Overexpression of BEN r mRNA was associated with fluconazole resistance in strain FR2; however, the other fluconazole-resistant strains, which were all crossresistant to other azoles, did not express elevated amounts of BEN r . Taken collectively, these data suggest that azole resistance in C. albicans might develop as a multistep process. Resistance to fluconazole can be acquired by mutations associated with increased expression of BEN r and/or CDR1, while other mutations causing increased CDR1 expression are associated with multiazole resistance. If such mutations can be acquired at a relatively high frequency, this would permit C. albicans cells to survive in the presence of fluconazole or other azoles and acquire further specific drug target mutations that might confer multidrug high-level resistance (such as that exhibited by strain Darlington).
It should be noted that there is still no direct evidence that Ben r or Cdr1 proteins bind and transport antifungal drugs. While it seems most logical to suggest that Ben r and Cdr1 are directly involved in azole drug efflux, it is now known that membrane transporters can regulate the activities of heterologous membrane channels (17) . It seems plausible then to suggest that Ben r and Cdr1 might impinge on the activities of other (as yet undefined) systems that are directly involved in conferring multidrug resistance. Such regulatory functions might be in keeping with recent evidence from other microbial drug efflux systems in which multiple interactive mechanisms for drug resistance are suggested (24) . It is important therefore that we define precisely the biochemical activities of Ben r and Cdr1 in order to understand the molecular basis of effluxmediated azole resistance in C. albicans.
